SLMP53-2 may represent a valuable contribution to the advancement of personalized melanoma therapy in comparison to other p53–MDM2 interaction inhibitors, such as nutlin-3a, which is only effective against wtp53-expressing tumours. This evidence concerns the gene TP53 and melanoma.